explore -WSS

explore

author：explore 2025-09-03 03:33:16 - browse：69214

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： The EU Joint Clinical Assessment needs to live up to its promise

entertainment

WSS

Cigna, Humana reportedly in talks to merge

ReNAgade cuts staff seven months after raising $300 million

Solve the antibiotic resistance crisis with preventive drugs

FDA gives detailed accounting of AI

UnitedHealth’s board chair also owns a personal investment firm

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Wikipedia

explore

hotspot

Bright Health sells Medicare Advantage business to Molina

FDA warns J&J's Abiomed: We will regulate your software

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

What don’t we know about an Alzheimer’s drug side effect?

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Researchers explore possible ties between long Covid, menopause

Guidelines to prevent youth baseball injuries need more muscle

Pharmacists can make shortage drugs, but at what cost?

Peter Hotez and the public health issue of online harassment

U.K. Biobank has 500,000 peoples' genome sequences available

focus

UnitedHealth’s Optum accused of antitrust violations in California

CEOs share strategies for surviving biotech slump

Pharmacists can make shortage drugs, but at what cost?

STAT Summit: Biotech founders on deal

Pharmacists can make shortage drugs, but at what cost?

STAT Readout Newsletter: Today's biggest biotech updates

hotspot

explore

entertainment

explore